PHOENIX, Jan. 18, 2008 (PRIME NEWSWIRE) -- Keller Rohrback, P.L.C. and Keller Rohrback L.L.P., with offices in Phoenix and Seattle respectively, (www.krclassaction.com) today announced that a class action Complaint has been filed in Arizona in Maricopa County Superior Court against the drug companies Merck & Co. Inc. and Schering-Plough Corporation. The Complaint was filed on behalf of all Arizona residents who took VYTORIN, a cholesterol reducing drug.
The Complaint includes claims for consumer fraud and requests medical monitoring for class members under Arizona law. Recently, Merck and Schering-Plough announced that the data from the ENHANCE clinical trials showed that patients who took VYTORIN (a combination of Zetia and Zocor) actually had an increase in the amount of plaque deposited in their arteries when compared to those patients who took Zocor alone. The data reflects that users of VYTORIN may be more at risk to have a heart attack, and have been exposed to an increased risk of liver damage, than those who took Zocor alone.
If you or someone you know is concerned about injuries suffered as a result of taking VYTORIN, please contact one of the following attorneys for a free consultation: Michael Woerner at (800)776-6044 (Seattle) or, Mark D. Samson at (602)230-6323 (Phoenix).
Keller Rohrback, P.L.C. and Keller Rohrback L.L.P. have successfully represented hundreds of clients injured by prescription drugs such as Fen-Phen, Baycol, and Vioxx. Our Complex Litigation Group is proud to offer its expertise in personal injury cases to clients nationwide.